Patient background
- ✓
- A 48-year old female with triple-negative and BRCA1/2-negative breast cancer was administered to a hospice.
- ✓
- Active disease progression after 21 courses of chemotherapy
- ✓
- Impaired quality of life
- ✓
- Limited ability to wear clothing due to metastatic lesions on the skin
- ✓
- Severe painkillers interfering with normal cognition
Treatment
- ✓
- Elenagen was applied intramuscularly at a dose of 2.5 mg weekly in combination with standard chemotherapy scheme CMF (cyclophosphamide, methotrexate, fluorouracil)
Result
- ✓
- Partial tumor regression (by 33%)
- ✓
- 19 weeks of progression-free survival
- ✓
- Increase of quality of life
- ✓
- Limited use of painkillers leading to complete recovery of cognition mode
- ✓
- Only limited discomfort due to the skin lesions
- ✓
- The patient retuned from a hospice to home
